Prominent NIHR Newcastle Biomedical Research Centre clinical academics attend leading international symposia to deliver research insights into liver disease.
Professor of Liver Immunology, Professor David Jones, and Professor of Experimental Hepatology, Professor Quentin Anstee will speak at events in the UK this September.
Shelia Sherlock event – London, 1st – 3rd September 2016
At the Sheila Sherlock Updates 2016, an event organised by University College London, experts are brought together to hear the latest from the current leading areas of hepatology.
On day 1, Professor David Jones, will deliver insight into ‘Advancements in the Understanding & Treatment of PBC’.
On day 2, Professor Quentin Anstee, will deliver a presentation on Genetic Determinants of NAFLD (Non-Alcoholic Fatty Liver disease).
Both have roles that span Newcastle University and the Newcastle upon Tyne Hospitals NHS Foundation Trust,
Clinical Hepatology Practice in 2016 – Birmingham, 2nd – 3rd September 2016
This two-day, international liver meeting, entitled, Clinical Hepatology Practice in 2016: From Science to Therapy, is to take place in Birmingham and will bring together scientists and clinicians who dedicate their research and practice to learning about liver disease and potential treatments.
Professor David Jones, will present to fellow hepatology colleagues from around the world within the ‘Autoimmune liver disease’ session on: What comes after UDCA in PBC?
UDCA is a type of drug used to manage Primary Biliary Cholangitis (PBC), as well as other chronic cholestatic diseases. Professor Jones will share his research on medication for the condition with colleagues in the field of hepatology.
Translating research into international patient care
The roles that Professor Jones and Professor Anstee hold within the NIHR Newcastle Biomedical Research Centre are in response to ‘Ageing Body’ research theme, which seeks to understand more about the long term conditions that affect the body, such as liver disease, heart disease and diabetes. With a better understanding, patients can be treated more effectively and receive care that is specific to their symptoms.
Director of the NIHR Newcastle Biomedical Research Centre (BRC), Professor Avan Sayer commented: “The purpose of the Newcastle BRC is to ensure research is translated into effective patient care. By sharing their expertise with international colleagues, Professor Jones and Professor Anstee are not only helping patients of the Newcastle upon Tyne Hospitals NHS Foundation Trust, but they are also sharing valuable research that may go towards changing care for patients in the UK and around the world, living with these conditions.”
Experts in liver disease
Due to the nature of their research and hospital roles, Professor Jones and Professor Anstee hold prominent positions across multiple organisations. Doing so is beneficial for patients, students and for the hospital trust areas in which they work, but can be complex to those outside of the industry. Their different roles are explained here;
Professor David Jones is a Professor of Liver Immunology within the Institute of Cellular Medicine at Newcastle University. This means his research, teaching and student supervision is linked to Newcastle University’s excellent reputation in liver disease research.
He is also and Dean for Faculty Trainees at the NIHR. The NIHR funded through the Department of Health to improve the health and wealth of the nation through research. It also involves training the researchers of the future through various study methods and Professor David Jones leads this area.
Within the NHS, he is a Consultant Physician at the Freeman Hospital, part of the Newcastle upon Tyne Hospitals NHS Foundation Trust. Here he treats patients living with long term and rare liver diseases.
Professor Quentin Anstee is Genomics Theme Lead for NIHR Newcastle Biomedical Research Centre, and for this role he examines the genetic reasons people may develop long term liver diseases.
He also holds the position of Professor of Experimental Hepatology with Newcastle University, with a particular focus on the pathogenesis and treatment of Non-Alcoholic Fatty Liver Disease (NAFLD/NASH), genetic and epigenetic modifiers of Hepatic Fibrosis progression. He co-ordinates the European Union Horizon 2020 funded EPoS: Elucidating Pathways of Steatohepatitis consortium and is actively involved in biomarker discovery projects and ongoing clinical trials of new therapies for NAFLD.
Clinically, he works directly with patients as a Consultant Hepatologist with the Freeman Hospital, part of the Newcastle upon Tyne Hospitals NHS Foundation Trust.
Both Professor Jones and Professor Anstee adopt a ‘bench to bedside’ approach, meaning they translate what is learned in a medical research environment into better patient care, and take patient experiences back to scientist research, in order to understand more about the conditions they see regularly in a clinical setting.